<SEC-DOCUMENT>0000000000-25-000507.txt : 20251121
<SEC-HEADER>0000000000-25-000507.hdr.sgml : 20251121
<ACCEPTANCE-DATETIME>20250116173606
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000000000-25-000507
CONFORMED SUBMISSION TYPE:	UPLOAD
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250116

FILED FOR:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			YD Bio Ltd
		CENTRAL INDEX KEY:			0002011674
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		UPLOAD
		SEC FILE NUMBER:	333-283428

	BUSINESS ADDRESS:	
		STREET 1:		955 WEST JOHN CARPENTER FREEWAY
		STREET 2:		SUITE 100-929
		CITY:			IRVING
		STATE:			TX
		ZIP:			75039
		BUSINESS PHONE:		619-500-7747

	MAIL ADDRESS:	
		STREET 1:		955 WEST JOHN CARPENTER FREEWAY
		STREET 2:		SUITE 100-929
		CITY:			IRVING
		STATE:			TX
		ZIP:			75039

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	True Velocity, Inc./DE
		DATE OF NAME CHANGE:	20240209
PUBLIC REFERENCE ACCESSION NUMBER:		0001213900-24-101742
</SEC-HEADER>
<DOCUMENT>
<TYPE>LETTER
<SEQUENCE>1
<FILENAME>filename1.pdf
<TEXT>
<PDF>
begin 644 filename1
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MPNSZ;)0,%!"$M_-LKT*OQ(/MIRP2KV_X70VK[W4%,S9*'WB'FFL[_.-M;AZ
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M\B-AN@'82/CSU(E-ZLR#D&9T92%<9AK07.=E5V!\0_,P\A+^I>4@-B3'XU$
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MM-"_-YZBZ<RA[W#(&K*!W9;(ID0[U+8/7_])9]Z)' ?F#9I46[6$3A&:--5
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M3-M%__3$W4$Z<W@*_6-=N#_KNO">ZEM!$6 /)R3?F;V01E,+00S^A6@]4I<
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M+G162LTU(E)"=AH4SWG5T%[3,*2QM^@QZ(S7M(F>@ZBSLLM%74"8O)A#XK\
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M2WD@:5!VF:Q0@,ZEZ!-18[U8"4VW*44VB?LD7CD52E2APLWG<*\X_ZMO:7[
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M@240&Y^X;NR(&@<6WW4N_%XQ$Q6%ZPYR\!PS*H?L;M(!TM &S-\5W+8KVS@
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M[;CAVX9(MZ<*U.;$MMJG!QREM/W>&VDKZ3EJLS0/YLM(R#>P(C[RMFN P5%
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M?4H!5]5=]K[UEJ+8733;9+=8("^T1-LL9%$EI3C>S]@OZ*?N&5*TW:2QU44
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MD\-2Z48@'2U:+O4S^]VC8@^<*N:HW@U-FKXLT;9Q*82%1R+X_9W\;65=LX6
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M7Z3)^="SR(EIG(3THC>L3\7.9GLQ3<[!YFCS )L!*F)X\7;)XTN^@HRL'&_
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M:A:A=X=D1AA7T!)B^6:!X?+SB[2+^Q'-[[I_(IW4+IJ.:MZ+]9UVC7;15]A
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MOICWS)"SM(LAC<T_2\O<LC:0U97:9-J0AU@3H[Y"N\A+LR\&2"=_!6NN:OV
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ME>>(O\]VVQ@1$1$1$1&1OQF6QNF/0(3,FC.+D&NXD\2_K--9N9_4+G)QC9A
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M
M
M
M
M
M
M
M                                  #/ %&5NID*96YD<W1R96%M"F5N
M9&]B:@IX<F5F"C @-S(*,# P,# P,# P," V-34S-2!F( HP,# P,#,R,34S
M(# P,# P(&X@"C P,# P,S0P,#<@,# P,# @;B *,# P,# S,C$Y.2 P,# P
M,"!N( HP,# P,# Q,#4U(# P,# P(&X@"C P,# P,# P,34@,# P,# @;B *
M,# P,# S,C@R-R P,# P,"!N( HP,# P,#,R.3$W(# P,# P(&X@"C P,# P
M,#,R-S0@,# P,# @;B *,# P,# P,3,U-2 P,# P,"!N( HP,# P,# Q,C(P
M(# P,# P(&X@"C P,# P,S,P.3<@,# P,# @;B *,# P,# S-#$S-2 P,# P
M,"!N( HP,# P,# U,#DU(# P,# P(&X@"C P,# P,#,U-C @,# P,# @;B *
M,# P,# P,S0R-2 P,# P,"!N( HP,# P,#,S,C<Y(# P,# P(&X@"C P,# P
M,#<S,C@@,# P,# @;B *,# P,# P-3,X,R P,# P,"!N( HP,# P,# U,C0X
M(# P,# P(&X@"C P,# P,S,T-C$@,# P,# @;B *,# P,# P.3,Q-R P,# P
M,"!N( HP,# P,# W-C$U(# P,# P(&X@"C P,# P,#<T.#$@,# P,# @;B *
M,# P,# S,S8T,R P,# P,"!N( HP,# P,#$Q-#4V(# P,# P(&X@"C P,# P
M,#DV,#4@,# P,# @;B *,# P,# P.30W," P,# P,"!N( HP,# P,#,S.#(U
M(# P,# P(&X@"C P,# P,3,V,#0@,# P,# @;B *,# P,# Q,3<T-" P,# P
M,"!N( HP,# P,#$Q-C Y(# P,# P(&X@"C P,# P,S(T-C,@,# P,# @;B *
M,# P,# Q-3<V,R P,# P,"!N( HP,# P,#$S.#DR(# P,# P(&X@"C P,# P
M,3,W-3<@,# P,# @;B *,# P,# S,C8T-2 P,# P,"!N( HP,# P,#$X,3DS
M(# P,# P(&X@"C P,# P,38P-3$@,# P,# @;B *,# P,# Q-3DQ-B P,# P
M,"!N( HP,# P,#,S,# V(# P,# P(&X@"C P,# P,C T.38@,# P,# @;B *
M,# P,# Q.#0X,B P,# P,"!N( HP,# P,#$X,S0V(# P,# P(&X@"C P,# P
M,S,Q.#@@,# P,# @;B *,# P,# R,C8V,B P,# P,"!N( HP,# P,#(P-S@U
M(# P,# P(&X@"C P,# P-3DS.34@,# P,# @;B *,# P,# R,#8T.2 P,# P
M,"!N( HP,# P,#,S,S<P(# P,# P(&X@"C P,# P,C0Y-3<@,# P,# @;B *
M,# P,# R,CDU,2 P,# P,"!N( HP,# P,#(R.#$V(# P,# P(&X@"C P,# P
M,S,U-3(@,# P,# @;B *,# P,# R-S$T,2 P,# P,"!N( HP,# P,#(U,C0W
M(# P,# P(&X@"C P,# P,C4Q,3$@,# P,# @;B *,# P,# S,S<S-" P,# P
M,"!N( HP,# P,#(Y,3 V(# P,# P(&X@"C P,# P,C<T,S$@,# P,# @;B *
M,# P,# R-S(Y-2 P,# P,"!N( HP,# P,#,S.3$V(# P,# P(&X@"C P,# P
M,S Y.#0@,# P,# @;B *,# P,# R.3,Y-2 P,# P,"!N( HP,# P,#(Y,C8P
M(# P,# P(&X@"C P,# P,S(U-30@,# P,# @;B *,# P,# S,3DY.2 P,# P
M,"!N( HP,# P,#,Q,C<S(# P,# P(&X@"C P,# P,S$Q,S@@,# P,# @;B *
M,# P,# S,C<S-B P,# P,"!N( HP,# P,#4Y-#DW(# P,# P(&X@"C P,# P
M-3DU-3<@,# P,# @;B *=')A:6QE<@H\/"])1"!;/#AB9#AC.3$U-F(Q-30T
M8S-A8V$V-3-C,34Y,6$V,#,Y/CPX8F0X8SDQ-39B,34T-&,S86-A-C4S8S$U
M.3%A-C S.3Y=+TEN9F\@,R P(%(O4F]O=" Q(# @4B]3:7IE(#<R/CX*)6E4
M97AT+4-O<F4M-RXR+C0*)6E497AT+7!D9DA434PM-"XP+C0*<W1A<G1X<F5F
-"C8P,#@P"B4E14]&"@$!

end
</PDF>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                            January 16, 2025

Ethan Shen, Ph.D
Chief Executive Officer
YD Bio Limited
12F., No. 3, Xingnan St.
Nangang Dist.
Taipei City 115001, Taiwan

Ethan Shen, Ph.D
Chief Executive Officer
YD Biopharma Limited
12F., No. 3, Xingnan St.
Nangang Dist.
Taipei City 115001, Taiwan

       Re: YD Bio Limited
           Amendment No. 2 to Registration Statement on Form F-4
           Filed December 20, 2024
           File No. 333-283428
Dear Ethan Shen Ph.D and Ethan Shen Ph.D:

       We have reviewed your registration statement and have the following
comments.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Amendment No. 2 to Registration Statement on Form F-4 filed December 20, 2024
Cover Page

1.     Please revise your cover page to briefly describe any material financing
transactions
       that have occurred since the initial public offering of Breeze Holdings
Acquisition
       Corp. or will occur in connection with the consummation of the de-SPAC
transaction.
       Refer to Item 1604(a)(2) of Regulation S-K.
 January 16, 2025
Page 2

2.     Please revise your cover page to clearly state the amount of the
compensation
       received or to be received by the SPAC sponsor, its affiliates and
promoters, including
       any securities issued or to be issued to the SPAC sponsor, in connection
with the
       business combination or any related financing transaction. Please
disclose whether
       this compensation and securities issuance may result in a material
dilution of the
       equity interests of non-redeeming shareholders who hold the securities
until the
       consummation of the de-SPAC transaction and provide a cross-reference to
the related
       disclosures in the prospectus. Refer to Item 1604(a)(3) of Regulation
S-K.
3.     We refer to your disclosure on pages 5 and 66 relating to the material
conflicts of
       interest in connection with the de-SPAC transaction. Please revise your
cover page to
       discuss any actual or potential sources of conflicts of interest between
the Sponsor, the
       SPAC   s officers, directors, affiliates or promoters, the target
company   s officers and
       directors, and the unaffiliated security holders as required by Item
1604(a)(4) of
       Regulation S-K. Please make conforming changes to the Summary section.
Refer to
       Item 1604(b)(3).
4.     Please prominently disclose that Breeze was delisted from Nasdaq as well
as the
       reason for, and date of, delisting.
5.     Please disclose the location of your auditor   s headquarters.
Questions and Answers about the Proposals
Q: What happens if the Business Combination is not completed?, page xii

6.     We note your disclosure in the Form 8-K filed December 23, 2024 that the
Breeze
       stockholders voted to approve the extension of Breeze   s business
combination
       deadline to June 26, 2025. In your revised disclosure relating to this
extension, please
       disclose the percentage of Breeze shareholders at the time of the
stockholder vote that
       voted to redeem their shares. Make conforming changes throughout your
filing.
Q: What vote is required to approve each proposal at the Special Meeting?, page
xix

7.     Please revise to clearly state whether or not the de-SPAC transaction is
structured so
       that approval of at least a majority of unaffiliated security holders of
Breeze is
       required. Please refer to Item 1606(c) of Regulation S-K.
Summary of the Proxy Statement/Prospectus, page 1

8.     Please revise to expand your discussion of the target, YD Biopharma, to
clearly state
       its current business operations as a supplier of clinical testing drugs
and nutritional
       products in Taiwan and the Asia region as discussed on page 179 and the
company   s
       history to date. For example, we note your disclosure on page F-16 that
Yong Ding
       Biopharma Co., Ltd. was incorporated in Taiwan on April 23, 2013 and
that YD
       Biopharma was incorporated in the Cayman Islands in March 2024 in
connection with
       the restructuring of Yong Ding and has operated primarily has a
development stage
       company since its formation. Please also provide additional and balanced
disclosure
       on the current state of YD Biopharma   s operations, including, but not
limited to, the
       early stage of development of its proposed cancer detection blood tests,
the
       company   s reliance on its licensing partnerships, and the company   s
history of
       operating losses and accumulated deficit to date. Please also make
conforming
 January 16, 2025
Page 3

       changes to the Business section for YD Biopharma.
9.     We refer to your disclosure on page 7 that the Breeze Board has
determined that the
       business combination is in the best interests of its shareholders.
Please revise your
       Summary disclosure to describe any material factors that the Breeze
Board considered
       in making this determination. Refer to Item 1604(b)(2) of Regulation
S-K.
10.    Please revise your Summary to provide a table showing the terms and
amount of the
       compensation received by the Breeze Sponsor, its affiliates and
promoters in
       connection with the business combination or any related financing
transaction. Please
       ensure that your revised disclosure addresses each aspect of Item
1604(b)(4) of
       Regulation S-K, including disclosure of the extent to which such
compensation and
       securities issuance has resulted or may result in material dilution of
the equity
       interests of non-redeeming shareholders of the SPAC outside of the
table.
11.    Please revise the Summary to provide a brief description of the material
terms of any
       material financing transactions that have occurred or will occur in
connection with the
       consummation of the business combination, the anticipated use of
proceeds from these
       financing transactions, and the dilutive impact, if any, of these
financing transactions
       on non-redeeming shareholders. Refer to Item 1604(b)(5) of Regulation
S-K.
12.    We refer to your disclosure on page 7 relating to the redemption rights
of Breeze
       shareholders. Please expand your disclosure in the Summary to discuss
the potential
       dilutive impact of redemptions on non-redeeming shareholders. Refer to
Item
       1604(b)(6) of Regulation S-K.
13.    Please revise your disclosure to address the following comments relating
to the Breeze
       Sponsor:

             Please revise to include a description of the general character of
the Breeze
           Sponsor   s business, where appropriate. Refer to Item 1603(a)(2) of
Regulation S-
           K;

             Please revise to describe the experience of the Sponsor, its
affiliates, and any
           promoters in organizing SPACs and the extent to which the Sponsor,
its affiliates,
           and the promoters are involved in other SPACs. Refer to Item
1603(a)(3); and

             Please revise to describe the material roles and responsibilities
of the Sponsor, its
           affiliates, and any promoters in directing and managing the SPAC   s
activities.
           Refer to Item 1603(a)(4).
14.    Please revise to disclose the nature and amounts of all compensation
that has been or
       will be awarded to, earned by, or paid to the Sponsor, its affiliates,
and any promoters
       for all services rendered or to be rendered to the SPAC and its
affiliates. Refer to Item
       1603(a)(6) of Regulation S-K.
15.    Please provide in tabular format the material terms of any agreements
regarding
       restrictions on whether the Sponsor and its affiliates may sell
securities of the SPAC.
       Please refer to Item 1603(a)(9).
 January 16, 2025
Page 4
16.    We note your disclosure on page v and vii that the Per Share Merger
Consideration
       means the number of Pubco Ordinary Shares resulting from    the product
of (x) each
       share of YD Biopharma Ordinary Shares that is issued and outstanding
immediately
       prior to the Effective Time (excluding any cancelled or dissenting YD
Biopharma
       Ordinary Shares) multiplied by (y) the Exchange Ratio (rounded to the
nearest whole
       number)    and that the Exchange Ratio is defined as an amount equal to
  (a)
       $647,304,110 divided by (b) the number of fully-diluted YD Biopharma
Ordinary
       Shares outstanding as of the Closing, further divided by (c) an assumed
value of
       Pubco Ordinary Shares of $10.00 per share.    Please amend your
disclosure
       throughout the filing to provide an estimated per share merger
consideration as of a
       recently practicable date.
Interests of Certain Persons in the Business Combination, page 7

17.    We note your disclosure on pages 7 and 68 of Breeze   s executive
officers and
       directors    other fiduciary duties or contractual obligations, other
than with respect to
       Breeze and/or the Sponsor. Please revise to disclose any material
interests held by the
       target company   s officers or directors that consist of any interest
in, or affiliation with,
       the Sponsor or the SPAC. Refer to Item 1605(d) of Regulation S-K.
Risk Factors, page 20

18.    We note that the BDO report concluded that as of January 1, 2024, 100%
of the
       common share equity value of Yong Ding was between $140.8 million and
$163.7
       million, and that CIAA concluded that as of June 30, 2024, the
investment value of
       YD Biopharma   s exclusive license to EG BioMed   s breast cancer
detection
       technology under the EG BioMed License Agreement was between $747.8
million to
       $769.6 million. Please revise to disclose the risk that the vast
majority of the
       transaction value is tied to an estimate of the value of a single
license agreement, if
       true.
There can be no assurance that the Pubco Ordinary Shares and the Pubco
Warrants..., page 46

19.    Please revise this risk factor to include clear disclosure that Breeze
was delisted and
       clear disclosure of where its stock trades, and that it is not traded on
a nationally
       recognized market. It appears you entered the Merger Agreement after
Breeze was
       delisted. If this is the case, please clarify how the delisting was
considered in the
       context of negotiations.
Unaudited Pro Forma Condensed Combined and Consolidated Financial Information,
page
70

20.    Please disclose any potentially dilutive securities.
Comparative Per Share Data, page 80

21.    We refer to your ownership table on page xiv and the table on page 81 of
the
       summary historical comparative share information for Breeze and YD
Biopharma.
       Please revise your disclosure to discuss all possible sources and the
extent of dilution
       that shareholders who elect not to redeem their shares may experience in
connection
       with the business combination, including sources not included in the
table with
 January 16, 2025
Page 5

       respect to the determination of net tangible book value per share, as
adjusted. In
       addition, we note that your ownership table on page xiv discloses
various redemption
       scenarios, including 25%, 50% and 75% redemption levels. Please revise
your
       sensitivity analysis on page 81 to include the various interim
redemption levels
       accordingly. In your revised disclosure in this section, please also
disclose the
       effective underwriting fee on a percentage basis for shares at each
redemption level
       presented in your sensitivity analysis related to dilution. Refer to
Item 1604(c) of
       Regulation S-K.
The Background of the Business Combination, page 89

22.    We note your disclosure on page 89 that following the completion of the
initial public
       offering, Breeze reviewed over 56 potential business combination targets
and entered
       into non-disclosure agreements with over 26 potential targets. Please
revise to address
       the following comments:

             Please clarify whether YD Biopharma was included in this initial
search for a
           potential target.

             You also disclose that Breeze's then-counsel mentioned that YD
Biopharma might
           be interested in pursuing a potential business combination with
Breeze in a
           conversation with Dr. Ramsey. Please expand your discussion to
provide
           additional detail of how YD Biopharma became interested in pursuing
a strategic
           transaction with Breeze.

             Please expand your disclosure relating to the 26 potential
business combination
           targets and amend your disclosure to describe in more detail the
reasons
           underlying Breeze management   s decision not to pursue a business
combination
           with TV Ammo, D-Orbit S.p.A and each of the 26 other potential
business
           combination targets.
23.    Please identify the individuals and/or parties who participated in the
meetings and
       discussions described throughout this section. By way of example only,
please
       identify the representatives of Breeze and YD Biopharma and their
financial and legal
       advisors.
24.    We note your disclosure on page 90 that Breeze and YD Biopharma began to
       negotiate a preliminary draft letter of intent regarding the potential
business
       combination on August 30, 2024 and that Breeze entered into a letter of
intent with
       YD Biopharma on September 6, 2024. Please revise to provide additional
detail
       regarding the letter of intent. By way of example only, please disclose
the material
       terms of the preliminary letter of intent, including the pre-transaction
equity value of
       YD Biopharma, and clarify whether subsequent drafts of the letter of
intent were
       exchanged until the letter of intent was executed on September 6, 2024,
and if so,
       please disclose the negotiations of the material terms of the letter of
intent. In your
       revised disclosure please also describe how the Breeze Board arrived at
the
       preliminary equity value of YD Biopharma in the letter of intent and the
pre-
       transaction equity value of $647,304,110. Please address in your
revisions the
 January 16, 2025
Page 6

       methodology employed in reaching the valuation, including the underlying
       assumptions and conclusions of the Breeze Board.
25.    We note your disclosure that after the parties entered into a letter of
intent on
       September 6, 2024, the Breeze Board approved the merger agreement on
September
       20, 2024 and the parties entered into the merger agreement on September
24, 2024.
       Please revise your background of the business combination section to
include a
       detailed discussion of negotiations relating to the material terms of
the transaction,
       including, but not limited to, the evolution of the transaction
structure, the merger
       consideration and enterprise value of YD Biopharma, the terms of the
lock-up
       agreements, sponsor support agreement, shareholder support agreement,
the terms of
       the PIPE financing, and post-governance terms. In your revised
disclosure, please
       explain the reasons for such terms, each party   s position on such
issues, the proposals
       and counter-proposals made during the course of negotiations, and how
you reached
       agreement on the final terms. As a related matter, where you disclose
general topics
       and agreements that were discussed at each meeting, please provide
additional detail
       regarding the substance of those discussions and material terms of the
relevant
       agreements.
26.    Please disclose any discussions about continuing employment or
involvement for any
       persons affiliated with Breeze before the merger, any formal or informal
commitment
       to retain the financial advisors after the merger, and any pre-existing
relationships
       between SPAC sponsors and additional investors.
27.    Please revise your disclosure with respect to I-Bankers and Northland,
the managing
       underwriters in Breeze   s initial public offering, to address the
following comments:

             We note your disclosure on pages 7, 84 and elsewhere in the
registration
           statement that pursuant to a business combination marketing
agreement you
           entered into with I-Bankers and Northland in connection with the
initial public
           offering, I-Bankers and Northland are entitled to receive cash fees
of $2,688,125
           and $474,375, respectively, that are only payable upon the closing
of the business
           combination. Please revise your disclosure to describe the role of
these financial
           advisors in the business combination, including the level of
diligence I-Bankers
           and Northland performed in connection with the transaction. Please
clearly
           describe any additional services each financial advisor or its
affiliates provided in
           connection with the transaction, such as for a private placement,
the related fees,
           and whether those fees are conditioned upon the completion of the
transaction.

             Please describe any relationship that existed between I-Bankers,
Northland and
           Breeze after the close of the IPO, including any financial or
merger-related
           advisory services conducted by I-Bankers and/or Northland. For
example, clarify
           whether I-Bankers or Northland had any role in the identification or
evaluation of
           business combination targets.
28.    We refer to your disclosure on page xii that parties intend to
consummate a PIPE
       financing, which is also a closing condition in the merger agreement.
Please expand
       your disclosure to clarify the current status of discussions and
negotiations regarding a
       PIPE transaction. To the extent that negotiations and marketing
processes for a PIPE
 January 16, 2025
Page 7

       are ongoing, please disclose material details of those processes,
including who
       selected the potential PIPE investors, what relationships the PIPE
investors have to
       Breeze, the Sponsor, YD Biopharma and its affiliates, the placement
agent and
       advisors, if any, and how the terms of the PIPE transaction were
determined. Please
       also revise your filing to include risk factor disclosure that addresses
how the failure
       to consummate a PIPE transaction could impact Pubco   s ability to
operate its business
       after the closing. Refer to Item 1605(b)(2) of Regulation S-K.
29.    Please revise your disclosure, where appropriate, to discuss both the
benefits and
       detriments of the business combination and any related financing
transactions to
       Breeze, the Breeze Sponsor, YD Biopharma and public stockholders. The
benefits and
       detriments of the business combination and any related financing
transaction must be
       quantified to the extent practicable. Refer to Item 1605(c) of
Regulation S-K.
The Business Combination, page 89

30.    Please revise to state whether or not a majority of the directors (or
members of similar
       governing body) who are not employees of Breeze has retained an
unaffiliated
       representative to act solely on behalf of unaffiliated security holders
for purposes of
       negotiating the terms of the de-SPAC transaction and/or preparing a
report concerning
       the approval of the de-SPAC transaction. Please refer to Item 1606(d) of
Regulation
       S-K.
31.    Please revise this section to expand the discussion of Breeze's and YD
Biopharma's
       reasons for engaging in the business combination and whether either
entity considered
       other transactions, such as YD Biopharma conducting a traditional IPO,
in lieu of a
       de-SPAC. In addition, discuss the reasons for the timing of the merger
for the parties.
       Refer to Item 1605(b)(3).
Breeze's Board of Directors' Reasons for the Approval of the Business
Combination, page 90

32.    We note your disclosure that the Breeze Board determined not to obtain a
fairness
       opinion in approving the business combination in light of Breeze   s
officers and
       directors    substantial experience in evaluating the operating and
financial merits of
       companies from a wide range of industries. Please revise your disclosure
here, and, as
       appropriate, throughout your filing, to provide additional detail
describing the
       qualifications and "substantial experience" of your officers and
directors that allowed
       the Board to determine that the business combination agreement and the
transactions
       thereby are advisable and in the best interest of shareholders.
33.    We refer to your disclosure that the Breeze Board reviewed and
considered two
       valuation reports that were commissioned and provided by YD Biopharma in
its
       decision to approve the business combination. Please revise to provide
the analysis
       and disclosure for each report as required by Item 1607(b) of Regulation
S-K.
34.    We note your disclosure on page 91 that the Breeze Board reviewed and
discussed
       financial projections prepared by YD Biopharma   s management team
before reaching
       its unanimous decision to approve the business combination. You also
state on page
       91 that    YD Biopharma did not provide its own forecasts to Breeze or
its board
       relating to financial metrics of the company,    but that the valuation
reports
       commissioned by YD Biopharma included certain forecasted financial
metrics of YD
 January 16, 2025
Page 8

       Biopharma. Please clarify whether YD Biopharma provided the Breeze Board
with its
       financial projections or revise to reconcile these disclosures
accordingly. If the Breeze
       Board considered certain financial projections prepared and provided by
YD
       Biopharma, please revise to include the disclosures required by Item
1609 of
       Regulation S-K.
35.    We refer to your disclosure on page 91 that the Breeze Board considered
an analysis
       of comparable target companies and research on comparable transactions
in reaching
       its decision to approve the business combination. Please clarify whether
the analysis
       and research of comparable companies and comparable transactions was
conducted by
       BDO Taiwan and China Intangible Assets Appraisement Co., Ltd. (   CIAA
). Please
       expand your disclosure in this section to describe in greater detail the
comparable
       companies analysis, including how the criteria for each of the
comparable companies
       was chosen and whether any companies meeting the selection criteria were
excluded
       from the analysis. In your revised disclosure, discuss the valuations of
the comparable
       companies and the analyses provided by BDO Taiwan and how the Breeze
Board
       applied the comparable companies analysis to determine the valuation for
YD
       Biopharma in greater detail. Please also provide the disclosure
requested above with
       respect to the comparable transactions analysis performed by CIAA. We
also note
       your statement that "no consideration was paid by Breeze to either BDO
Taiwan or
       CIAA in connection with the two reports." Please disclose the fees paid
to each entity
       by any party to the business combination, not just Breeze.
36.    You disclose on page 91 that the Breeze Board reviewed a    study of
analyst reports
       and market trends in the industries.    Please revise to clarify whether
your advisors
       prepared such study and/or any analyst reports and expand your
disclosure of such
       studies and report. To the extent that such study or report is a report,
opinion, or
       appraisal under Item 4(b) of Form F-4, please provide the information
requested
       thereby or tell us why you believe this is not required.
Potential Actions to Satisfy Merger Agreement Closing Conditions, page 96

37.    We note the disclosure on page 49 indicating that the Breeze Initial
Stockholders and
       Breeze   s directors, officers, advisors or their affiliates    may
purchase shares of
       Breeze common stock in the open market. Please provide your analysis on
how such
       potential purchases would comply with Rule 14e-5. For instance, we note
your
       disclosure that    any such privately negotiated purchases may be
effected at purchase
       prices that are in excess of the per-share pro rata portion of the Trust
Account.    Refer
       to Tender Offer Rules and Schedules Compliance and Disclosure
Interpretation
       166.01.
Representations and Warranties, page 99

38.    Please revise your list of representations and warranties to describe
the material terms
       of each item rather than providing a summary list.
At-The-Market Facility, page 105

39.    Please revise to further describe the At-The-Market Facility the parties
to the Merger
       Agreement are required to enter prior to Closing.
 January 16, 2025
Page 9

Material U.S. Federal Income Tax Considerations, page 112

40.    Please revise to provide the federal income tax consequences of the
de-SPAC
       transaction to (i) the SPAC, (ii) the target company, (iii) target
security holders, and
       (iv) SPAC security holders. Refer to Item 1605(b)(6) of Regulation S-K.
Please make
       conforming changes throughout your filing, including to your Questions
and Answers
       on page xi.
41.    We refer to your disclosure on page 62 that the exchange of Breeze
common stock for
       Pubco ordinary shares pursuant to the merger agreement is    expected to
qualify as a
       tax-free exchange for U.S. federal income tax purposes    and your
disclosure on page
       144:    due to the factual uncertainty, Woolery & Co is unable to opine
with respect to
       the Breeze Merger   s qualification as part of an exchange subject to
Section 351 of the
       Code.    Please revise your disclosure in this section to clearly state
the tax
       consequences to U.S. holders of Breeze securities. Please remove
language stating
       that    generally    certain tax consequences will apply or assuming
certain
       consequences. If there is uncertainty regarding the tax treatment of the
transactions,
       counsel may (1) issue a    should    or    more likely than not
opinion to make clear that
       the opinion is subject to a degree of uncertainty and (2) explain why it
cannot give a
       firm opinion. For further guidance, see Staff Legal Bulletin No. 19.
Advancing Noninvasive Cancer Detection with Circulating Cell-Free DNA ("cfDNA")
Methylation Technology, page 149

42.    We refer to your disclosure on page 204 that YD Biopharma and its
subsidiary, Yong
       Ding Biopharm Co., Ltd., entered into an exclusive licensed patent and
know-how
       agreement with EG BioMed Co., Ltd. (   EG BioMed   ) to    acquire
the licensed patent
       of Methylation analysis technology for application in pancreatic cancer
and
       subsequently entered into an additional license agreement with EG BioMed
for the
       application of the Methylation analysis technology in breast cancer. You
state on page
       149 that the parties have agreed to jointly develop products using EG
BioMed   s patent
       and technology in the United States. Please expand your disclosure in
the Business
       section to discuss in greater detail the nature and scope of the
intellectual property
       transferred and clarify who owns the jointly-developed intellectual
property, each
       parties    rights and obligations, the royalty term, termination
provisions, aggregate
       future potential milestones payments to be paid, and the aggregate
amounts paid to
       date under each agreement (including any up-front fees), as applicable.
Additionally,
       we note that on page 20 you state the following: "Accordingly, we could
be obligated
       to pay fees or other amounts to EG BioMed even though we have generated
no or
       limited revenue." Please revise to disclose the fees or other amounts
referenced here.
       Please also clarify your disclosure throughout the registration
statement, if true, that
       YD Biopharma has licensed such intellectual property from EG BioMed and
file the
       agreements as exhibits to the registration statement.
43.    We refer to your statement on page 150 that EG BioMed has submitted a de
novo
       application to the FDA for its breast cancer blood tests and received a
decision letter
       from the FDA outlining several points to be addressed within 180 days.
Please revise
       to discuss the issues to be addressed with the FDA and specify the dates
on which EG
       BioMed submitted its de novo application and received the FDA   s
response.
 January 16, 2025
Page 10

44.    You disclose on page 150 that you hope the EG BioMed patent for core
methylation
       detection of pancreatic cancer will be "95% sensitivity, 93% specificity
and 94%
       accuracy." A similar statement appears on page 151 with respect to your
breast cancer
       testing: "This technology will allow us to develop, market and sell
noninvasive tests
       to diagnose breast cancer with only 8 milliliters of blood for
circulating with 95%
       sensitivity, 90% specificity and 95% accuracy" and on page 154, where
you state that
       your test exhibits "[o]ver 90% precision in cancer detection." Please
revise your
       disclosure to discuss the meaning and significance of these rates and
measurement
       terms. Please disclose any clinical studies or statistical analysis
performed, including
       the discussion of statistical significance, relating to EG BioMed   s
methylation
       analysis to date, if any. Please also revise to expressly state that
your products have
       not been approved by the FDA or comparable regulatory bodies in any
jurisdictions.
       For example, we note statements like the following on page 154: "With
rigorous
       validation using extensive clinical samples, our licensed technology
ensures precision
       and reliability." Please remove all statements that present your
conclusions regarding
       the efficacy of your tests in development as this is a determination
within the authority
       of the FDA and comparable regulatory bodies.
45.    We note your disclosure on page 151 of your plans to use EG BioMed   s
technology to
       develop a pancreatic cancer screening test as a laboratory developed
test (LDT). You
       also state that you are considering strategies to advance the FDA   s
clearance or
       approval of your pancreatic cancer screening test. Please revise your
disclosure in the
       Summary and throughout the registration statement to briefly discuss the
expected
       FDA classification of the cancer screening tests as medical devices into
one of three
       classes (Class I, Class II and Class III). Please also revise your
disclosure on page 158
       to explain the FDA   s classification of medical devices into Class I,
Class II and Class
       III depending on its level of risk. Describe also the Breakthrough
Devices Program or
       Safer Technologies Program (SteP) for Medical Devices you mention.
46.    We note your disclosure on page 151 that EG BioMed is    actively
preparing its
       pancreatic cancer blood test for regulatory submission,    is evaluating
expedited
       pathways, and intends to file a formal request for a pre-submission
meeting with the
       FDA. Please revise to clarify why EG BioMed is preparing the blood test
for
       submission and meeting with the FDA instead of you, and discuss the
status and
       expected timeline for EG BioMed   s request for a pre-submission meeting
with the
       FDA and for regulatory submission. Please also specify when EG BioMed
entered
       into a strategic partnership with a U.S.-based CRO to support the
regulatory
       submission process to the FDA. We note your disclosure on page 152 that
EG
       BioMed entered into a contract with Arbelos Genomics Inc. in October
2024.
47.    Throughout this section where you discuss your plans for growth, such as
the
       opportunities to    collaborate with over 2,000 clinics in the U.S. as
well as hospitals,
       insurance companies and pharmaceutical companies    on page 150 and to
 introduce
       new drugs and treatments for conditions such as dry eye disease,
glaucoma, and
       corneal repair    on page 154, disclose any steps taken towards growth
in these areas,
       any significant regulatory or other requirements the company must meet
to achieve
       these goals, and the planned timing for achieving growth in such areas.
 January 16, 2025
Page 11
Information about YD Biopharma, page 149

48.    Please clarify the meaning of scientific or technical terms the first
time they are used
       in order to ensure that lay readers will understand the disclosure. For
example, please
       briefly explain what you mean by DNA methylation, exosome, apoptosis,
stromal
       tissues, and mesenchymal stem cells. Please also define terms, such as
MTS, CAP
       application and CAP inspection on pages 152-153.
49.    We note your disclosure on page 182 that YD Biopharma   s net revenue
increased by
       10% for the six months ended June 30, 2023 compared to six months ended
June 30,
       2023 due to the sales of medical and other related products, including
the
       manufactured nutritional products in Taiwan. You also disclose that the
increase in
       revenue was primarily due to the increase in sales demand of the
products from the
       post COVID-19 era. We also refer to your statement on page 187 that YD
Biopharma
       engages in    the sales of drugs and medical and other related materials
to corporate and
       retail customers.    Please revise your disclosure to address the
following comments:

             Please revise your disclosure here and elsewhere in the
registration statement to
           describe in greater detail each of YD Biopharma   s drug, medical
and nutritional
           products, including a breakdown of YD Biopharma   s top products by
revenue;

             Please specify the types of products from the    post COVID-19 era
   and clarify
           whether YD Biopharma expects the continued increase in the sales
demand for
           these products; and

             Please clarify whether YD Biopharma manufactures the
manufactured nutritional
           products    or any other products sold to its corporate and retail
customers.
50.    We note your statement on page 187 that YD Biopharma   s products are
marketed and
       sold primarily to corporate and retail customers in Taiwan and that all
sales and
       property and equipment are within the Asia region. You also disclose on
page F-24
       that Customers A and B accounted for over 70% of YD Biopharma   s sales
and that
       Customers A and D accounted for nearly 80% of the accounts receivable
balances for
       the fiscal year ended December 31, 2023. Please revise to identify your
top customers,
       including whether they are corporate or retail customers, and specify
the relevant
       jurisdictions within the Asia region. Please also disclose whether you
have entered
       into any agreements with your top customers, and if so, provide a brief
description of
       the material terms of such agreements, such as the termination
provisions and any
       minimum purchase requirements. If material, please also file the
agreements as
       exhibits to the registration statement as required by Item 601(b)(10) of
Regulation S-
       K, or explain to us why you believe you are not required to do so. In
addition, amend
       your risk factor disclosure to discuss the risks related to this
customer concentration.
51.    We refer to your disclosure on page 181 that your ability to control
your materials
       cost is dependent on your ability to source raw materials from reliable
suppliers.
       Please revise to clarify whether YD Biopharma currently relies on any
single-source
       suppliers for its raw materials. Please expand your disclosure, where
appropriate, to
       identify the suppliers on which you rely and the material terms of your
agreements
 January 16, 2025
Page 12

       with such parties. Refer to Item 101(h)(4)(v) of Regulation S-K.
52.    We note your disclosure on page 41 that YD Biopharma faces intense
competition
       from U.S. and foreign companies focusing on cancer blood tests and
pharmaceutical
       products, including major multinational diagnostic and pharmaceutical
companies,
       and specialized biotechnology firms that have greater financial and
other resources.
       Please revise to include disclosure that identifies your top competitors
in the
       pancreatic and breast cancer diagnostics, contact lens, and glaucoma and
dry eye
       syndrome treatment markets. Please also disclose whether any of your
competitors in
       the cancer diagnostic market also utilize cfDNA methylation technology
in their
       products. Additionally, with respect to the eye disease market
specifically, we note
       your statement on page 42: "Exosome therapeutics are novel and unproven
therapies,
       with no exosome therapeutic approved to date   .To date, other efforts
to leverage
       natural exosomes have generally demonstrated an inability to generate
exosomes with
       predictable biologically active properties or to manufacture exosomes at
suitable scale
       to treat more than a small number of patients   .Our success will depend
on our ability
       to demonstrate that our exosomes can overcome these challenges." Please
revise to
       clarify how your exosome therapies are planned to differ from the
exosome therapies
       developed by these competitors or others that have not resulted in
approved products.
53.    We refer to your disclosure that the global cancer diagnostic market is
projected to
       grow from an estimated $102.24 billion in 2022 to $162.57 billion in
2030, with a
       compound annual growth rate of 6.1%. Given your disclosure that you are
seeking
       regulatory approval and/or certification for your cancer detection
products in the U.S.
       and Taiwan and primarily have marketed and sold your products to date in
Taiwan,
       please revise to disclose the estimated market for cancer diagnostic
tests in the United
       States and Taiwan. Please also revise to make conforming changes
relating to your
       disclosure of the estimated global market sizes for pancreatic cancer
diagnostics,
       breast cancer diagnostics, contact lenses, contact lenses solution,
glaucoma treatment,
       and dry eye syndrome. Where you reference anticipated compound annual
growth
       rates for each market, please expand your disclosure to discuss any
material
       assumptions underlying these projections.
54.    We note your statement on page 148: "By leveraging translational
medicine expertise
       of our management team, we accelerate the journey from research to
clinical trials,
       positioning YD Biopharma as a leader in the industry." Please revise to
provide
       support for this statement. Additionally, please revise to describe the
clinical testing of
       your products that you or your licensors have completed, if any, and
revise here to
       state, as you do on page 158, that have not yet obtained FDA clearance
or approval for
       any of your cancer screening testing products.
Breast Cancer Testing, page 151

55.    We refer to your estimated timeline for your pancreatic and breast
cancer blood tests
       services and products disclosed on page 152. Please revise to provide
greater detail
       with respect to each milestone listed and clarify whether you have
completed each
       scheduled milestone to date. For example, please clarify whether the
cfDNA
       methylation blood test refers to your pancreatic and breast cancer blood
tests and
       discuss the design, scope, and the primary endpoint of the Favor V
Leiden (Molecular
 January 16, 2025
Page 13

       Pathology) clinical test. Revise also to describe what you mean when you
refer to a
       Medicare application as well as validation of your cfDNA Methylation
Blood Tests.
Our Eye Disease Treatment Business, page 153

56.    We note your disclosure of the table on page 153 of your
eye-products-related
       development and production line schedule and have the following
comments:

             Please expand your disclosure with respect to each product outside
of the table.
           As examples only, please discuss the mechanisms of action, timeline
of
           development, any regulatory requirements and/or approvals including
the
           applicable jurisdiction (such as whether the products are regulated
as medical
           device or drugs), as applicable.

             Please state that any approvals or certifications that you have
not yet obtained
           may not be obtained in the timeframe you have suggested and may
never be
           obtained. Please also tell us why you think it is appropriate to
include a column
           for "sales schedule" for unapproved products, and why you think it
is appropriate
           to include events as far out as 2030 and 2031.

             We refer to the third and fourth rows in the table, which refers
to the appointment
           of the Yujun CRO company. Please revise your disclosure to describe
the role of
           the Yujun CRO company and clarify whether you have entered into an
agreement
           with this company, and if so, please briefly describe the material
terms of such
           agreement and file the agreement as an exhibit or explain to us why
you believe
           you are not required to do so. Refer to Item 601(b)(10) of
Regulation S-K.
57.    We refer to your disclosure on page 204 relating to your license
agreement with 3D
       Global Biotech Inc. (   3D Global   ). Please revise your disclosure in
this section to
       discuss the material terms of the 3D Global license agreement, including
when the
       last-to-expire licensed patent is scheduled to expire, the aggregate
amounts paid to
       date under the agreement (including the payment of any up-front or
execution fees),
       the aggregate future potential milestone payments to be paid, and the
termination
       provisions. Please make any conforming changes to your disclosure on
page 204. We
       note the term of the license is for "20 years after all the relevant
products are
       launched." Please revise to list the products and current developmental
status of each.
       Additionally, we note your statement on page 21 that you are required to
pay the
       patent application fees (if any), patent maintenance fees, and project
development
       fees. Please revise to disclose the project development fees or an
estimate thereof.
Our Clinical Testing Drug Supply Business, page 154

58.    We note your disclosure on page 179 that YD Biopharma was appointed as a
clinical
       testing drug supplier by a top five global pharmaceutical company in
2015 and has
       since expanded its offering to include development and supply of
ancillary products.
       You disclose on page 154 that YD Biopharma has been appointed    by
leading
       pharmaceutical companies in Taiwan    as a supplier of clinical testing
drugs. Please
       revise to identify the    top five global pharmaceutical company    and
provide support
 January 16, 2025
Page 14

       for the statement that they are top five, and clarify whether YD
Biopharma has
       entered into supply agreements with such global pharmaceutical company
and other
       leading pharmaceutical companies in Taiwan, and if so, provide a brief
description of
       the material terms of each agreement that YD Biopharma has entered into
and file
       such agreements as exhibits to the registration statement or explain to
us why you
       believe you are not required to do so. Refer to Item 601(b)(10) of
Regulation S-K.
Employees, page 155

59.    We note you have five full-time employees and two part-time employees.
Please
       revise to state whether you plan to hire additional employees or
contract with third
       parties to fulfil your business objectives. For example, we note your
statement on
       page 154: "Utilizing the technology we have licensed from 3D Global, we
intend to
       develop several new advanced drugs and treatments for conditions such as
dry eye
       disease, glaucoma, and corneal repair" and your statement on page 179:
"The success
       of YD Biopharma will be dependent on an employee base that includes
specialists
       with extensive medical and biological training."
Intellectual Property Portfolio, page 155

60.    We refer to your disclosure on pages 151 and 154 relating to the patents
and
       technology you have licensed from EG BioMed and 3D Global. Please expand
your
       disclosure in this section to identify for each of YD Biopharma   s
material patents and
       patent applications, as applicable, whether such patent or patent
application is owned
       or licensed, the scope and technology of each patent or patent
application, the type of
       patent protection, jurisdiction and expiration dates. Consider adding
tabular disclosure
       in addition to the narrative for ease of use.
Properties, page 155

61.    We note your disclosure that YD Biopharma currently rents its executive
office space
       in Taipei City, Taiwan. Please briefly describe the material terms of
such lease
       agreement and also file the lease agreement as an exhibit or provide us
with an
       analysis supporting a determination that you are not required to file it
as an exhibit.
       Refer to Item 601(b)(10)(ii)(D) of Regulation S-K.
Beneficial Ownership, page 234

62.    Please revise your disclosure to identify the natural person or persons
who have
       voting and/or investment control of the shares held by Vision AP on page
235.
Financial Statements of YD Biopharma Limited and Subsidiary
Revenue Recognition, page F-43

63.    Please disclose the revenue disaggregation as required by ASC 606.
 January 16, 2025
Page 15
Note 8. Intangible Assets, page F-50

64.    Please disclose the payment terms and accounting for the remaining $4
million due to
       3D Global. For amounts due when certain conditions and milestones are
satisfied and
       completed, identify these conditions and milestones and the related
amounts. In
       addition, please disclose your accounting for the potential royalties
due 3D Global and
       EG BioMed.
General

65.    With a view toward disclosure, please tell us whether your sponsor is,
is controlled
       by, has any members who are, or has substantial ties with, a non-U.S.
person. Please
       also tell us whether anyone or any entity associated with or otherwise
involved in the
       transaction, is, is controlled by, has any members who are, or has
substantial ties with,
       a non-U.S. person. Also revise your filing to include risk factor
disclosure that
       addresses how this fact could impact your ability to complete your
initial business
       combination. For instance, discuss the risk to investors that you may
not be able to
       complete an initial business combination with a target company should
the transaction
       be subject to review by a U.S. government entity, such as the Committee
on Foreign
       Investment in the United States (CFIUS), or ultimately prohibited.
Further, disclose
       that the time necessary for government review of the transaction or a
decision to
       prohibit the transaction could prevent you from completing an initial
business
       combination and require you to liquidate. Disclose the consequences of
liquidation to
       investors, such as the losses of the investment opportunity in a target
company, any
       price appreciation in the combined company, and the warrants, which
would expire
       worthless. We refer to your risk factor disclosure in Breeze Holdings
Acquisition
       Corp.   s preliminary proxy statement on Schedule 14A filed on November
19, 2024.
66.    Please note the registration statement must be signed by the registrant,
its principal
       executive officer or officers, its principal financial officer, its
controller or principal
       accounting officer, at least a majority of the board of directors or
persons performing
       similar functions and its authorized representative in the United
States. See Instruction
       1 to Signatures on Form F-4. Note also that information concerning each
member of
       management and each director is required by Item 6 of Form 20-F. We note
that the
       Management of YD Bio section on page 178 contains only the biography of
the CEO.
67.    Please revise to include the disclosure required by Part II of Form F-4.
 January 16, 2025
Page 16

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Christie Wong at 202-551-3684 or Michael Fay at
202-551-3812 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Jane Park at 202-551-7439 or Margaret Sawicki at 202-551-7153 with any
other
questions.




                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Industrial
Applications and
                                                           Services
cc:   Mathew J. Saur, Esq.
      Marc Rivera, Esq.
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
